Gliceida María Galarza Fortuna
No Rating Available
(Learn About Our Rating System)

Gliceida María Galarza Fortuna, MD

Languages spoken: English, Spanish

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Hematology/Oncology
1950 Circle of Hope
Salt Lake City , UT 84112
801-585-0100
Get Directions

  • Dr. Gliceida M. Galarza Fortuna is an Assistant Professor in the Division of Hematology & Hematologic Malignancies at the University of Utah. She completed her Hematology-Oncology fellowship at the University of Utah, where she served as Chief Fellow. During her training, she developed a clinical and research interest in plasma cell dyscrasias.

    Her work focuses on novel therapeutic strategies for multiple myeloma, with an emphasis on immunotherapies, CAR T-cell therapy, and the biology of relapsed and refractory disease. Her research has been presented at national and international scientific meetings and published in several high-impact medical journals.

    Dr. Galarza Fortuna earned her medical degree from UNIBE School of Medicine in Santo Domingo, Dominican Republic, and completed her internal medicine residency at Mount Sinai Medical Center. She specializes in the care of patients with multiple myeloma, amyloidosis, Waldenström’s macroglobulinemia, and other plasma cell disorders.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    National Board of Medical Examiners

  • Dr. Gliceida M. Galarza Fortuna is an Assistant Professor in the Division of Hematology & Hematologic Malignancies at the University of Utah. She completed her Hematology-Oncology fellowship at the University of Utah, where she served as Chief Fellow. During her training, she developed a clinical and research interest in plasma cell dyscrasias.

    Her work focuses on novel therapeutic strategies for multiple myeloma, with an emphasis on immunotherapies, CAR T-cell therapy, and the biology of relapsed and refractory disease. Her research has been presented at national and international scientific meetings and published in several high-impact medical journals.

    Dr. Galarza Fortuna earned her medical degree from UNIBE School of Medicine in Santo Domingo, Dominican Republic, and completed her internal medicine residency at Mount Sinai Medical Center. She specializes in the care of patients with multiple myeloma, amyloidosis, Waldenström’s macroglobulinemia, and other plasma cell disorders.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Assistant Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    National Board of Medical Examiners

    Education history

    Fellowship Hematology & Oncology - University of Utah Spencer Fox Eccles School of Medicine Chief Fellow
    Fellowship Hematology & Oncology - University of Utah Spencer Fox Eccles School of Medicine Fellow
    Residency Internal Medicine - Mount Sinai Medical Center Academic Chief Resident
    Residency Internal Medicine - Mount Sinai Medical Center Resident
    Professional Medical Medicine - Universidad Iberoamericana M.D.
    Undergraduate Major: Psychology; Minor: Health Sciences - Manhattanville University B.A.

    Selected Publications

    Journal Article

    1. Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, ONeil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta S (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). J Immunother Cancer, 13(3). (Read full publication)
    2. Ozay ZI, Jo Y, Galarza Fortuna G, Hage Chehade C, Gebrael G, Ostrowski M, Sayegh N, Anderson E, Jaime-Casas S, Zugman M, Mathew Thomas V, Maughan BL, Agarwal N, Pal SK, Swami U (2025). Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US. JAMA Netw Open, 8(3), e251201. (Read full publication)
    3. Campbell P, Gebrael G, Narang A, Chehade CH, Thomas VM, Galarza Fortuna G, Sayegh N, Tripathi N, Tandar C, Dal E, Li H, Swami U, Agarwal N, Maughan BL (2024). Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix. Ther Adv Urol, 16, 17562872241293779. (Read full publication)
    4. Dal E, Srivastava A, Chigarira B, Hage Chehade C, Matthew Thomas V, Galarza Fortuna GM, Garg D, Ji R, Gebrael G, Agarwal N, Swami U, Li H (2024). Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma. Diagnostics (Basel), 14(17). (Read full publication)
    5. Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, Srivastava A, Nordblad B, Dal E, Narang A, Brundage J, Campbell P, Galarza Fortuna G, Hage Chehade C, Maughan BL, Agarwal N, Swami U (2024). Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor. Cancer, 130(15), 2621-2628. (Read full publication)
    6. Zanwar S, Galarza Fortuna GM, Sborov DW (2024). Risk-adapted treatment in multiple myeloma: Does more make it merrier? Br J Haematol, 205(3), 767-769. (Read full publication)
    7. Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, Mathew Thomas V, Galarza Fortuna G, Narang A, Campbell P, Gupta S, Maughan BL, Roy S, Agarwal N, Swami U (2024). Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers. JAMA Netw Open, 7(7), e2423186. (Read full publication)
    8. Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal N (2024). Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting. Prostate, 84(9), 888-892. (Read full publication)
    9. Mathew Thomas V, Sayegh N, Chigarira B, Gebrael G, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, Agarwal N, Swami U (2024). Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy. Eur Urol Oncol. (Read full publication)
    10. Sborov DW, Fortuna GG, Hayden PJ (2024). Sequence not salvage. Br J Haematol, 204(5), 1590-1592. (Read full publication)
    11. Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, Gebrael G, Hage Chehade C, Sayegh N, Galarza Fortuna G, Ji R, Campbell P, Li H, Agarwal N, Gupta S, Swami U (2024). Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US. JAMA Netw Open, 7(5), e249417. (Read full publication)
    12. Mathew Thomas V, Chigarira B, Gebrael G, Sayegh N, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, Agarwal N, Swami U (2024). Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI. JCO Precis Oncol, 8, e2300574. (Read full publication)
    13. Tripathi N, Fortuna GG, Gebrael G, Dal E, Mathew Thomas V, Gupta S, Swami U (2023). Predictors of response to neoadjuvant therapy in urothelial cancer. Crit Rev Oncol Hematol, 194, 104236. (Read full publication)
    14. Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J, 14(1), 20. (Read full publication)
    15. Gebrael G, Fortuna GG, Sayegh N, Swami U, Agarwal N (2023). Advances in the treatment of metastatic prostate cancer. Trends Cancer, 9(10), 840-854. (Read full publication)
    16. Gebrael G, Fortuna GG, Agarwal N (2023). Developing an Ideal Risk Stratification Model for Metastatic Renal Cell Carcinoma. JAMA Oncol, 9(8), 1033-1035. (Read full publication)
    17. Fortuna GMG, Guerra V, Chaaya G (2021). Acquired factor V inhibitor presenting as life threatening bleeding after initiation of apixaban. Haemophilia, 27(5), e636-e637. (Read full publication)
    18. Dvir K, Galarza-Fortuna GM, Haines JM, Gines P, Ruiz AL, Rodriguez E (2021). Real-World Data on Liquid Biopsy Use in Non-Small Cell Lung Cancer in the Community Setting. J Immunother Precis Oncol, 4(1), 1-5. (Read full publication)
    19. Fortuna GMG, Rios P, Rivero A, Zuniga G, Dvir K, Pagacz MM, Manzano A (2020). Papillary Thyroid Carcinoma With Cystic Changes in a Patient With Prior History of Toxic Nodule. J Investig Med High Impact Case Rep, 8, 2324709620942672. (Read full publication)

    Review

    1. Galarza Fortuna GM, Dvir K (2020). Circulating tumor DNA: Where are we now? A mini review of the literature. [Review]. World J Clin Oncol, 11(9), 723-731. (Read full publication)
    2. Galarza Fortuna GM, Singh A, Jacobs A, Ugalde I (2020). Lung Adenocarcinoma Presenting as Multiple Thromboembolic Events: A Case Report and Review of the Literature. [Review]. J Investig Med High Impact Case Rep, 8, 2324709620969482. (Read full publication)

    Case Report

    1. Cortez N, Berzosa M, Mahfouz M, Dvir K, Galarza Fortuna GM, Ben-David K (2020). Diagnosis and Treatment of Metastatic Disease to the Pancreas. J Laparoendosc Adv Surg Tech A, 30(9), 1008-1012. (Read full publication)
    2. Dvir K, Galarza-Fortuna GM, Willet A, Febres-Aldana C, Cortez N, Rapaka S, Coombs A, Goldberg R, Schwartz M, Ben-David K (2020). A Rare Case of Light Chain Amyloidosis of the Gastrointestinal Tract. Case Rep Surg, 2020, 1921805. (Read full publication)
    3. Febres-Aldana AJ, Febres-Aldana CA, Dvir K, Galarza-Fortuna G, Schwartz M, Medina AM, Sriganeshan V (2020). Reactivation of Epstein-Barr Virus Presenting as Massive Splenomegaly after Initiation of Golimumab Treatment. Case Rep Hematol, 2020, 3641813. (Read full publication)
    4. Dvir K, Fortuna GMG, Schwartz M (2019). Delayed Presentation of Thymoma-Related Aplastic Anemia: An Unusual Presentation of a Rare Complication. J Hematol, 8(4), 160-164. (Read full publication)
    5. Galarza Fortuna GM, Dvir K, Febres-Aldana C, Schwartz M, Medina AM (2019). Primary Central Nervous System Lymphoma in an Immunocompetent Patient Presenting as Multiple Cerebellar Lesions: A Case Report and Review of Literature. J Investig Med High Impact Case Rep, 7, 2324709619893548. (Read full publication)

    Editorial

    1. Galarza Fortuna GM, Maughan BL (2024). The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the modern era. Transl Androl Urol, 13(5), 915-919. (Read full publication)

    Letter

    1. Galarza Fortuna GM, Swami U, Gupta S (2025). Response to: Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)". [Letter to the editor]. J Immunother Cancer, 13(5). (Read full publication)
    2. Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. [Letter to the editor]. Leuk Lymphoma, 65(9), 1362-1365. (Read full publication)